Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 12/20 | 0.49 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | KCNH2 | Q12809 | 4/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | GHSR | Q92847 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2791379 | 0.86 | CYP2D6 (0.49) | CYP2D6KCNH2NPC1RAB9AGHSR | |
| SCHEMBL2795644 | 0.86 | CYP2D6 (0.55) | CYP2D6KCNH2GHSRCYP1A2CYP2C9 | |
| SCHEMBL2793327 | 0.83 | CYP2D6 (0.55) | CYP2D6KCNH2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2795487 | 0.83 | CYP2D6 (0.47) | CYP2D6KCNH2NPC1RAB9ACYP1A2 | |
| SCHEMBL2792914 | 0.82 | CYP2D6 (0.49) | CYP2D6KCNH2GHSR | |
| SCHEMBL2792275 | 0.81 | ESR2 (0.51) | CYP2D6KCNH2NPC1RAB9ACYP1A2 | |
| SCHEMBL12337449 | 0.79 | GPR119 (0.45) | CYP2D6GPR119KCNH2NPC1RAB9A | |
| SCHEMBL2791858 | 0.78 | DRD2 (0.45) | CYP2D6GPR119KCNH2NPC1RAB9A | |
| SCHEMBL12337217 | 0.78 | CYP2D6 (0.80) | CYP2D6KCNH2CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2796125 | 0.77 | CYP2D6 (0.48) | CYP2D6KCNH2GHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8263607-B2 | 1-substituted tetrahydroisoquinoline compound | ASTELLAS PHARMA INC. (JP) | 2012-09-11 | — | — | US | disclosed |
| US-20100168154-A1 | 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | disclosed |
| US-20100168154-A1 | 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2010-07-01 | — | — | US | disclosed |
| EP-2149560-A1 | 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | Astellas Pharma Inc. (JP) | 2010-02-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100168154-A1 | 1-SUBSTITUTED TETRAHYDROISOQUINOLINE COMPOUND | CACNA1S, CACNA1E, CACNA1B | CYP2D6 834/4885GPR119 409/4885KCNH2 83/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.